

PC17416
Application No. 09/674,815AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claims 1-33 (canceled)

RECEIVED
CENTRAL FAX CENTER

APR 02 2007

Claim 34 (Currently amended): A solid pharmaceutical composition comprising:

- (a) a neutral α amino acid, and
- (b) a ~~4-amino-3-substituted butanoic acid derivative selected from the group consisting of~~ selected from gabapentin and pregabalin, and
- (c) optionally, one or more auxiliary agents, wherein the pharmaceutical composition is a solid.

Claim 35 (Previously presented): The composition of Claim 34, wherein the neutral α -amino acid is one or more selected from: glycine, phenylglycine, hydroxyphenylglycine, dihydroxyphenylglycine, L-alanine, hydroxy-L-alanine, L-leucine, hydroxy-L-leucine, dihydroxy-L-leucine, L-norleucine, methylene-L-norleucine, L-ketonorleucine, L-isoleucine, hydroxy-L-isoleucine, dihydroxy-L-isoleucine, L-valine, hydroxy-L-valine, L-isovaline, L-norvaline, hydroxy-L-norvaline, hydroxy-L-ketonorvaline, L-methionine, L-homomethionine, L-ethionine, L-threonine, acetyl-L-threonine, L-tryptophan, hydroxy-L-tryptophan, methyl-L-tryptophan, L-tyrosine, hydroxy-L-tyrosine, methyl-L-tyrosine, bromo-L-tyrosine, dibromo-L-tyrosine, 3,5-diiodo-L-tyrosine, acetyl-L-tyrosine, chloro-L-tyrosine, L-m-tyrosine, L-levodopa, L-methyldopa, L-thyroxine, L-serine, acetyl-L-serine, L-homoserine, acetyl-L-homoserine, ethyl-L-homoserine, propyl-L-homoserine, butyl-L-homoserine, L-cystine, L-homocystine, methyl-L-cysteine, allyl-L-cysteine, propyl-L-cysteine, L-phenylalanine, dihydro-L-phenylalanine, hydroxymethyl-L-phenylalanine, L-aminobutyric acid, L-aminoisobutyric acid, L-ketoaminobutyric acid, dichloro-L-aminobutyric acid, dihydroxy-L-aminobutyric acid, phenyl-L-aminobutyric acid, L-aminovaleric acid, L-aminohydroxyvaleric acid, dihydroxy-L-aminovaleric acid, L-aminoisovaleric acid, L-

After Final Amendment, Page 2 of 8

PC17416

Application No. 09/674,815

aminohexanoic acid, methyl-L-aminohexanoic acid, L-aminoheptanoic acid, L-aminooctanoic acid, and citrulline, and the D- and DL-forms thereof.

Claim 36 (Previously presented): The composition of Claim 35, wherein the neutral α -amino acid is one or more selected from:

glycine, phenylglycine, hydroxyphenylglycine, dihydroxyphenylglycine, L-alanine, hydroxy-L-alanine, L-leucine, hydroxy-L-leucine, dihydroxy-L-leucine, L-isoleucine, hydroxy-L-isoleucine, dihydroxy-L-isoleucine, L-valine, hydroxy-L-valine, L-isovaline, and the D- and DL- forms thereof.

Claim 37 (Previously presented): The composition of Claim 34, wherein a total amount of the neutral α -amino acid is in the range of 0.001 - 80 moles per mole of the 4-amino-3-substituted-butanoic acid derivative.

Claim 38 (Currently amended): The composition of Claim 34, wherein the compound 4-amino-3-substituted butanoic acid derivative is gabapentin.

Claim 39 (canceled)

Claim 40 (New): The composition of Claim 34, wherein the compound is pregabalin.

After Final Amendment, Page 3 of 8